Go Pro
→ A new kind of civil war is coming after election day? (From Stansberry Research) (Ad)tc pixel Free KTTAW Stock Alerts

Pasithea Therapeutics (KTTAW) Competitors

$0.0013 0.00 (-53.96%)
Closing price 09/16/2026 04:49 PM Eastern
Extended Trading
$0.00 0.00 (0.00%)
As of 09/16/2026 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KTTAW vs. ALVOW, APLMW, BIAFW, BIVIW, and CDIOW

Should you buy Pasithea Therapeutics stock or one of its competitors? Pasithea Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), bioAffinity Technologies (BIAFW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pasithea Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

In the previous week, Alvotech had 4 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for Alvotech and 0 mentions for Pasithea Therapeutics. Alvotech's average media sentiment score of 0.20 beat Pasithea Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Neutral
Pasithea Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.95MN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Summary

Alvotech beats Pasithea Therapeutics on 3 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Apollomics?

Pasithea Therapeutics (NASDAQ:KTTAW) and Apollomics (NASDAQ:APLMW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Pasithea Therapeutics' average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company Overall Sentiment
Pasithea Therapeutics Neutral
Apollomics Neutral

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Apollomics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

Apollomics beats Pasithea Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Pasithea Therapeutics compare to bioAffinity Technologies?

Pasithea Therapeutics (NASDAQ:KTTAW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for bioAffinity Technologies and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.88 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Neutral
bioAffinity Technologies Negative

Summary

bioAffinity Technologies beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Pasithea Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Pasithea TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Pasithea Therapeutics N/A N/A N/A

In the previous week, BioVie had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for BioVie and 0 mentions for Pasithea Therapeutics. BioVie's average media sentiment score of 0.37 beat Pasithea Therapeutics' score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Neutral
Pasithea Therapeutics Neutral

Summary

BioVie beats Pasithea Therapeutics on 2 of the 2 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Cardio Diagnostics?

Pasithea Therapeutics (NASDAQ:KTTAW) and Cardio Diagnostics (NASDAQ:CDIOW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Pasithea Therapeutics' average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score.

Company Overall Sentiment
Pasithea Therapeutics Neutral
Cardio Diagnostics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/AN/AN/AN/A
Cardio Diagnostics$14.45KN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A N/A N/A
Cardio Diagnostics N/A N/A N/A

Summary

Cardio Diagnostics beats Pasithea Therapeutics on 1 of the 1 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KTTAW vs. The Competition

Export
MetricPasithea TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.90B$7.24B$13.19B
Dividend YieldN/A3.64%2.57%12.81%
P/E RatioN/A14.23274.9325.38
Price / SalesN/A1,419.61646.0189.45
Price / CashN/A108.9076.2551.42
Price / BookN/A15.4510.466.33
Net IncomeN/A-$22.86M$3.49B$358.33M
7 Day PerformanceN/A-1.21%0.59%1.12%
1 Month PerformanceN/A-3.29%-1.74%-2.39%
1 Year PerformanceN/A37.74%18.13%5.35%

Pasithea Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KTTAW
Pasithea Therapeutics
N/A$0.00
-54.0%		N/A-91.8%$0.00N/AN/A3
ALVOW
Alvotech
N/A$0.30
flat		N/A-66.1%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
+0.7%		N/A-39.3%$0.00$8.50MN/A59
BIAFW
bioAffinity Technologies
N/A$0.60
+0.8%		N/A+296.0%$0.00$5.85MN/A10
BIVIW
BioVie
N/A$0.37
+1.1%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KTTAW) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The hidden costs of a hands-off retirement account
Contributing to your 401(k) consistently is good financial behavior - but contributing and optimizing are two ...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Iran War: Why Is Trump Protecting THEM?
A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...
Banyan Hill Publishing | Sponsoredtc pixel